Home  /  Resource Library  /  Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Results of study investigating rituximab biosimilar CT-P10 for treatment of follicular lymphoma.